Compare GTBP & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTBP | ADTX |
|---|---|---|
| Founded | 1965 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 1.1M |
| IPO Year | 2016 | 2020 |
| Metric | GTBP | ADTX |
|---|---|---|
| Price | $0.42 | $3.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 799.3K | 133.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.75 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $133,985.00 |
| Revenue This Year | N/A | $15,768.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.40 | $0.02 |
| 52 Week High | $3.73 | $12.92 |
| Indicator | GTBP | ADTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.51 | 88.76 |
| Support Level | $0.41 | $0.76 |
| Resistance Level | $0.59 | $3.75 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | 0.01 | 0.19 |
| Stochastic Oscillator | 6.00 | 80.39 |
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.